期刊文献+

间歇性内分泌治疗老年人晚期前列腺癌的临床疗效分析 被引量:7

Clinical efficacy of intermittent androgen suppression treatment of advanced prostate cancer in elderly patients
原文传递
导出
摘要 目的 探讨间歇性内分泌治疗老年晚期前列腺癌的临床治疗效果及其安全性. 方法 选取78例老年晚期前列腺癌患者为研究对象,随机分为观察组(39例)和对照组(39例),观察组间歇性内分泌治疗;对照组持续性内分泌治疗. 结果 观察组患者内分泌治疗时间比对照组长(P<0.001);观察组治疗12个月后生活质量优于对照组(均P<0.05);观察组贫血、潮热和肝功能异常等不良反应发生率比对照组低(P<0.05). 结论 间歇性内分泌治疗老年晚期前列腺癌可明显推迟雄性激素非依赖时间,提高患者生活质量,减少药物用量,降低贫血、潮热和肝功能异常等不良反应发生率. Objective To explore clinical effect and safety of intermittent androgen suppression treatment of advanced prostate cancer in elderly patients.Methods 78 patients with advanced prostate cancer were enrolled,and randomly divided into the observation group and the control group (n=39 each).Patients in observation group were treated with intermittent androgen suppression treatment.Patients in control group were treated with persistent androgen suppression treatment.Results The time of therapy was much longer in observation group than in control group (P< 0.001).Quality of life was better in observation group than in control group (P<0.05).The incidences of adverse reactions including anemia,fever and abnormal liver function were lower in observation group than in control group (all P<0.05).Conclusions Intermittent androgen suppression treatment prolongs time to androgen-independent progression,improve the quality of life,reduce drug dosage and the incidence of adverse reactions in the treatment of advanced prostate cancer in the elderly.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2014年第9期980-982,共3页 Chinese Journal of Geriatrics
关键词 前列腺肿瘤 激素替代疗法 Prostatic neoplasms Hormone replacement therapy
  • 相关文献

参考文献7

二级参考文献106

共引文献57

同被引文献53

  • 1巩传凤,刘畅,王岚,于泳江.老年中晚期前列腺癌同期调强放疗联合内分泌治疗的疗效[J].中国老年学杂志,2014,34(10):2744-2745. 被引量:15
  • 2吴剑平,孙宏斌,朱佳庚,苏江浩,徐郑,许露伟,窦全亮,贾瑞鹏.更换抗雄药物治疗初始内分泌治疗失效的晚期前列腺癌[J].泌尿外科杂志(电子版),2014,6(4):10-13. 被引量:4
  • 3赫捷,陈万青.2012中国肿瘤登记年报[M].北京:军事医学科学出版社,2012:12-25.
  • 4Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2014, 136(5) : 359 -386.
  • 5Vander-Griend DJ, Litvinov IV, Isaacs JT. Conversion of an drogen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in e-myc regulation[J].Int J Biol Sci, 2014,10 : 627-642.
  • 6Mikkola A, Am J, Rannikko S, et al. Prognostic grouping of metastatic prostate cancer using conventional pretreatment prognostic factors[J] .Stand J Urol Nephrol, 2009,43(4): 265-270.
  • 7Sasaki T, Onishi T, Hoshina A. Cut off value of time to pros- tate-specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer[J].Endocrine Related Cancer,2012, 19(5) :725- 730.
  • 8Banefelt J, Liede A, Mesterton J, et al. Survival and clinical metastases among prostate cancer patients treated with andro- gen deprivation therapy in Sweden[J].Cancer Epidemiol,2014, 38(4) :442-447.
  • 9Center MM, Jemal A, Lortet Tieulant J, et al. International variation in prostate cancer incidence and mortality rates[J]. Eur Urol, 2012,61 ( 6), 1079-1092.
  • 10Siegel R, Naishadham D,Jemal A.Cancer statistics 2013[J]. CA Cancer J Clin, 2013,63(1) :11-30.

引证文献7

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部